Rejuvenate Boimed

This AI-enabled clinical-stage biotech company develops combination therapeutics to treat age-related diseases by targeting multiple biological pathways. Its lead candidate, RJx-01, is currently in Phase 2 clinical trials for the treatment of sarcopenia and muscle weakness in patients with Chronic Obstructive Pulmonary Disease (COPD). The company utilizes a proprietary platform to identify and reposition existing drugs to address mitochondrial dysfunction, inflammation, and fibrosis.